Silvana Lanzalone
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The TALAPRO-3 study design: a plain language summary.
Journal: Future oncology (London, England)
Published: October 25, 2024
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Journal: Future oncology (London, England)
Published: October 26, 2023
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 11, 2021
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Journal: Cancer research and treatment
Published: December 30, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 03, 2020
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
Journal: The oncologist
Published: November 21, 2019
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 17, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026